Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

219.12 +0.72 (+0.33%)
Streaming Delayed Price Updated: 12:06 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
News headline image
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA 
From ResMed Inc.
Via GlobeNewswire
News headline image
Stryker Stock Sees RS Rating Treks Higher To 71 ↗
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
News headline image
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
(RMD) - Analyzing ResMed's Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today ↗
 
Via Benzinga
News headline image
(RMD) - Analyzing ResMed's Short Interest ↗
 
Via Benzinga
News headline image
Why ResMed Stock Is Soaring Today ↗
Investors liked the healthcare technology company's latest quarterly update. 
Via The Motley Fool
News headline image
Why NYSE:RMD qualifies as a good dividend investing stock. ↗
Why the dividend investor may take a look at RESMED INC (NYSE:RMD). 
Via Chartmill
News headline image
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
News headline image
Betting on Nvidia: 3 ETFs to Own for Exposure to the AI Giant ↗
Explore three ETFs with Nvidia exposure to capitalize on the future of AI without having to pick a single winner. 
Via InvestorPlace
Topics Artificial Intelligence ETFs
News headline image
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
News headline image
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
The alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes. 
From MatrixCare
Via GlobeNewswire
News headline image
All-Time Highs In Sight: The Critical Signals You Can't Ignore ↗
Is the S&P 500 showing signs of a sustainable rally, or are we headed for a pullback? 
Via Talk Markets
Topics Stocks
News headline image
ResMed Announces Participation in the RBCCM Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
Top Research Reports For Apple, Linde & Comcast ↗
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Comcast Corporation (CMCSA​​​​​​​). 
Via Talk Markets
News headline image
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78 ↗
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78. 
Via Investor's Business Daily
News headline image
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes ↗
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates. 
Via Investor's Business Daily
News headline image
ResMed Analysts Boost Their Forecasts After Better-Than-Expected Earnings ↗
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet ↗
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. 
Via Benzinga
Topics Economy
News headline image
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024 ↗
RMD stock results show that ResMed beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher ↗
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
News headline image
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank ↗
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
News headline image
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test ↗
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea. 
Via Investor's Business Daily
News headline image
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. (NYSE: UBER). 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.